EquityZen Growth Technology Fund LLC - Series 1687
Raised
$258K
Investors
18
Min Invest
$10,000
AltStreet Analysis
·Generated from EDGAR primary sources
EquityZen Growth Technology Fund LLC - Series 1687 is a Delaware pooled investment fund vehicle filed by EquityZen Advisors LLC and Philip Haslett that raised $258,000 from 18 investors under Rule 506(b) and Section 3(c)(1). The offering has a $10,000 minimum investment and is part of EquityZen's private equity platform, which operates approximately 150 related EDGAR entities following a serialized SPV structure.
This filing is consistent with EquityZen's established single-deal SPV model in the private equity secondary market, using the typical 506(b)/3(c)(1) exemption structure for accredited investors. The $10,000 minimum investment represents a low entry point relative to traditional private equity vehicles, enabling broader access to late-stage startup equity positions.
Data Flags
EDGAR Filing Data
Form D — Primary Source
View on SEC.govRelated Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
EquityZen Advisors LLC
Executive Officer, Director · New York, NY
Philip Haslett
Executive Officer, Director · New York, NY
Is this your offering?
Claim this profile to add contact information, team members, LinkedIn profiles, fund history, and additional financial data. EDGAR-sourced data and AltStreet analysis cannot be edited, but corrections can be requested for verifiable inaccuracies.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. AltStreet analysis (summaries, flags, category context) is generated by Claude from this primary source data and reviewed for accuracy. Platform-provided information (if present) is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. EDGAR data is verified read-only — platforms may request factual corrections for demonstrable inaccuracies by contacting research@altstreet.investments. This page does not constitute investment advice.
